arrow
M

Martin Förster

University of London
H指数:60
被引数:2.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial

通过姑息性放疗和ATR抑制实现肿瘤控制和免疫激活,PATRIOT Part C:一项 Ib 期临床试验

2025-08-010
OAAI
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
2024-11-011
PRE
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
2024-01-168
OAAI
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

基于人工智能的模型ANORAK改善肺腺癌的组织病理学分级

2024-01-102
OAAI
DETERMINE: A pioneering UK precision medicine trial for rare cancers

确定: 英国针对罕见癌症的开创性精密医学试验

2023-10-010
PRE
Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
2023-10-010
OAAI
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

单药Divarasib (GDC-6036) 在具有KRAS G12C突变的实体瘤中

2023-08-2495
OA
Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
2023-04-147
PRE
Body composition and lung cancer-associated cachexia in TRACERx

TRACERx中的身体成分和肺癌相关的恶病质

2023-04-1233
OAAI
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

TRACERx中肺腺癌形态学的进化特征

2023-04-1231
OAAI